Prostate-Specific Antigen (PSA)

← Back to Lab Reference Library

Category: Hormone Health  |  Also known as: PSA, Total PSA, Free PSA, Prostate-Specific Antigen  |  Sample: Serum (fasting not required; avoid ejaculation 48 hours prior)

1. What This Test Measures

Prostate-specific antigen (PSA) is a serine protease enzyme produced exclusively by the epithelial cells of the prostate gland. Its physiological function is to liquefy seminal coagulum after ejaculation, facilitating sperm motility. PSA is present in seminal fluid at concentrations approximately one million times higher than in blood. Small quantities of PSA leak into the bloodstream from the prostate, and the serum concentration reflects the total volume, cellular activity, and integrity of prostate tissue.

The critical distinction that most patients and many physicians fail to make: PSA is a prostate tissue marker, not a prostate cancer marker. Any process that increases the volume of prostate tissue, disrupts the cellular architecture that normally contains PSA within the gland, or increases the metabolic activity of prostate cells will elevate serum PSA. This includes benign prostatic hyperplasia (BPH), prostatitis, urinary tract infection, recent ejaculation, vigorous cycling, and prostate manipulation, in addition to prostate cancer.

PSA circulates in two forms: complexed PSA (bound to alpha-1-antichymotrypsin and other serum proteins) and free PSA (unbound). The ratio of free to total PSA provides additional diagnostic information: cancer cells tend to produce more complexed PSA, so a low free PSA ratio (below 10%) raises suspicion for malignancy, while a high free PSA ratio (above 25%) favors benign disease. This distinction is most useful when total PSA falls in the 4 to 10 ng/mL diagnostic gray zone.

2. Why This Test Matters

• Prostate cancer screening: despite its limitations as a cancer-specific marker, PSA remains the most widely used screening tool for prostate cancer. When interpreted in clinical context (velocity, density, free ratio, age, family history), PSA identifies men who benefit from further evaluation
• Testosterone therapy monitoring: PSA is a required monitoring marker for all men on testosterone replacement therapy. A baseline PSA before testosterone initiation establishes the reference point for all subsequent monitoring. Testosterone does not cause prostate cancer, but it stimulates prostate tissue and can accelerate occult disease if present
• BPH assessment: PSA correlates with prostate volume and is used to assess the degree of benign prostatic enlargement and monitor response to treatment (5-alpha-reductase inhibitors reduce PSA by approximately 50%)
• Prostatitis detection: sudden PSA elevation with urinary symptoms, pelvic pain, or fever suggests prostatitis, which requires antimicrobial treatment and repeat PSA after resolution
• PSA velocity: the rate of PSA change over time is more clinically meaningful than any single PSA value. A PSA velocity greater than 0.75 ng/mL per year raises concern regardless of the absolute PSA level. Serial measurements at consistent intervals establish the velocity trend
• Post-treatment surveillance: after prostatectomy, PSA should be undetectable; any detectable PSA indicates residual or recurrent disease. After radiation, a sustained rise from the post-treatment nadir (Phoenix definition: nadir plus 2.0 ng/mL) defines biochemical recurrence

3. Standard Lab Reference Range

Age Group	Standard Upper Limit	Notes
40 to 49	2.5 ng/mL	Lowest expected range; baseline recommended at age 40
50 to 59	3.5 ng/mL	Prostate growth begins; BPH contribution increases
60 to 69	4.5 ng/mL	BPH prevalence high; clinical context essential
70 to 79	6.5 ng/mL	Age-related elevation; velocity more important than absolute value

4. Optimal Functional Medicine Range

PSA Level	Functional Interpretation
Below 1.0 ng/mL	Optimal: lowest risk; excellent baseline for testosterone therapy candidacy
1.0 to 2.0 ng/mL	Good: low risk; standard for men under 60 with no prostate symptoms
2.0 to 4.0 ng/mL	Monitor: establish velocity trend; evaluate free PSA ratio if rising; consider prostate volume assessment
4.0 to 10.0 ng/mL	Gray zone: free PSA ratio, PSA density, velocity, and clinical correlation required to guide further evaluation
Above 10.0 ng/mL	Evaluate: urology referral for biopsy consideration unless a clear benign cause (acute prostatitis, UTI) is identified

5. PSA in the Complete Men's Health Panel

PSA is one component of a comprehensive men's health assessment:

Marker	What It Adds	FM Optimal
PSA (this page)	Prostate tissue status; cancer screening baseline	Below 2.0 ng/mL
Total Testosterone	Primary androgenic status	600 to 900 ng/dL
Free Testosterone	Bioavailable androgen; more clinically relevant than total	Upper third of range
SHBG	Binding protein; determines free testosterone availability	20 to 40 nmol/L
Estradiol	Aromatization monitoring; excess drives prostate growth	20 to 35 pg/mL (men)
DHEA-S	Adrenal androgen reserve; aging biomarker	Upper third of age range

6. Symptoms Associated With PSA Elevation

7. What Causes Elevated PSA

• Benign prostatic hyperplasia (BPH): the most common cause of PSA elevation. Prostate volume increases with age, and more prostate tissue produces more PSA. BPH affects approximately 50% of men by age 50 and 80% by age 80
• Prostatitis: inflammation of the prostate (bacterial or non-bacterial) disrupts the cellular architecture that normally contains PSA within the gland, releasing PSA into the bloodstream. Acute prostatitis can elevate PSA to 20 ng/mL or higher transiently
• Prostate cancer: malignant prostate cells produce PSA, but cancer is only one of many causes of PSA elevation. The probability of cancer at PSA 4 to 10 ng/mL is approximately 25%, meaning 75% of biopsies in this range find no cancer
• Recent ejaculation: ejaculation can elevate PSA for 24 to 48 hours. Patients should abstain from ejaculation for 48 hours before PSA testing
• Vigorous exercise: cycling, horseback riding, and other activities that compress the perineum can transiently elevate PSA
• Urinary tract infection: UTI produces prostate inflammation and PSA elevation; retest after UTI resolution
• Prostate manipulation: digital rectal exam, catheterization, and prostatic massage elevate PSA transiently
• Elevated estradiol: excess estrogen drives prostate tissue growth and can contribute to both BPH and PSA elevation in men with high aromatase activity. Monitoring estradiol is essential in men on testosterone therapy

8. How to Optimize PSA and Prostate Health

9. Related Lab Tests

10. When Testing Is Recommended

• Baseline at age 40 for all men to establish a reference PSA value (earlier if family history of prostate cancer or African American heritage)
• Annual screening after age 50 (or after age 40 with risk factors); shared decision-making regarding screening frequency is recommended
• Before initiating testosterone replacement therapy: mandatory baseline. Recheck at 3 months, 6 months, 12 months, then annually
• Any new lower urinary tract symptoms (LUTS): frequency, urgency, hesitancy, weak stream, nocturia
• Pelvic pain, dysuria, or hematuria suggesting prostatitis or urinary pathology
• Family history of prostate cancer (first-degree relative): begin screening at age 40
• After prostatectomy or radiation: post-treatment surveillance per oncological protocol
• Serial measurements for PSA velocity calculation: minimum two values at least 6 months apart to establish a meaningful trend

11. Clinical Perspective

12. Frequently Asked Questions